Αρχική World News Five-Year Outcomes with CAR T Cell Therapy

Five-Year Outcomes with CAR T Cell Therapy

The results of 5-year follow-up in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma who were treated with CD19-directed, 4-1BB costimulated chimeric antigen receptor  (CAR) T cells (tisagenlecleucel) were reported on 18 February 2021 in The New England Journal of Medicine. The researchers from the University of Pennsylvania in Philadelphia, PA, US reported that most responses observed at 1 year were sustained at 5 years. No unexpected late safety concerns emerged in their single centre study.

The authors wrote that data on outcomes beyond 2 years after CAR T cell infusion are limited. They previously reported 28-month outcomes from the NCT02030834 study and in the latest article they report the results of the 5-year outcomes. Patients were followed for a median of 60.7 months.

Complete or partial responses were observed in 14 of 24 patients with DLBCL with best overall response 58%, and 11 of 24 patients (46%) having a complete response. At 5 years, progression-free survival was 31% (95% confidence interval [CI] 14 to 51). The median duration of response was 61.4 months with 60% of patients having a sustained response at 5 years.

Among patients with follicular lymphoma, complete or partial responses were observed in 11 of 14 patients with best overall response 79%, and 10 of 14 (71%) having a complete response. At 5 years, 43% of patients (95% CI 18 to 66) were progression-free. The median duration of response has not been reached and 60% had a sustained response at 5 years.

Lymphodepletion regimens varied, but did not affect clinical outcomes.

In patients who had complete remissions beyond 1 year, the CAR19 transgene was continuously detectable throughout the follow-up period in 6 of 12 patients by quantitative polymerase-chain-reaction assay; transgene could not be detected in 4 patients between 32.7 and 47.8 months, and the remaining patients had CAR19 transgene levels that alternated between detectable and undetectable levels. Among 18 patients who had a relapse of lymphoma within 1 year, only 1 had loss of transgene persistence. Among 5 patients who had a relapse beyond 1 year, 3 had undetectable transgene levels.

Among all patients who had relapse or progression of lymphoma, only 1 of 12 had loss of CD19 expression on tumour cells, assessed by flow cytometry, despite persistence of CAR19 transgene. No patient who had a relapse of lymphoma after 1 year had loss of CD19 expression on tumour cells by flow cytometry.

The median time from the start of infusion to resolution of all cytopenias was 56 days.

Within 2 years, 11 of 16 patients who were in complete remission beyond 1 year had recovery of B cells, and 9 of 11 had detectable CAR19 transgene at the time of B cell recovery. At 5 years, 11 of 16 patients had normal IgM levels, 9 of 16 had normal IgA levels, and 6 of 16 had normal IgG levels. Intravenous immunoglobulin treatment was started in 6 of 22 patients who had a response. All patients who remained in remission beyond 1 year recovered normal CD3, CD4, and CD8 T cell counts.

Secondary cancers occurred in 6 of 38 patients (16%).

No cases of replication-competent lentivirus were detected.

The University of Pennsylvania lymphoma programme investigators commented that although this was a single centre study with a relatively small number of patients, the results of 5-year follow-up indicate that alternative approaches to lymphodepletion are feasible, and cellular and humoral immunity often recover.

The study was supported by Novartis and by a grant from the Lymphoma Research Foundation.


Chong EA, Ruella, M, Schuster SJ. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. N Engl J Med 2021; 384:673-674
DOI: 10.1056/NEJMc2030164.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Making Important Decisions During Cancer: A Survivor’s Story

Bethany Hart lives with her husband Kevin, sons, and 3 dogs in the suburbs of Indianapolis, Indiana. She is a survivor of small cell neuroendocrine cervical cancer....

Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer

October 26, 2021, by NCI Staff Atezolizumab (Tecentriq) is approved as an additional treatment for some patients with stage II to IIIA (pictured) non-small cell...

Cure Probability Models for Evaluation of Patients with a Previous Cancer Diagnosis for Solid Organ Transplantation

Findings from a first study that applied a formal statistical framework to inform the evaluation of transplant candidates with a previous cancer diagnosis were...

Teacher Reads To Students One Day After Having Brain Surgery

Meucci - who had her surgery on a Wednesday - was going live from her intensive care unit hospital room that very next Thursday...

6 things you need to know about cervical screening

This article was originally published in 2017 during Cervical Screening Awareness Week. It has now been reviewed and updated. Cervical screening, also known as the...

EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan

On 14 October 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...